Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Passage BioPASG +2.28%32 3-Year EBITDA Growth Rate is 34.90% as of Mar. 2026, which is 144% above its 10-year median of 14.30. GuruFocus rates PASG with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, Passage Bio ranks better than 72.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Passage Bio was 34.90% per year. The lowest was -98.70% per year. And the median was 14.30% per year.
Passage Bio (NAS:PASG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Passage Bio 3-Year EBITDA Growth Rate Related Terms
PASG vs CTXR, HIND, GTBP: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Passage Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Passage Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.90% mean?
Passage Bio (PASG) has a 3-Year EBITDA Growth Rate of 34.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Passage Bio and its competitors. This is 144% above median its historical median of 14.30. According to the industry distribution chart, Passage Bio ranks #308 out of 1136 companies in the Biotechnology industry, placing it in the top 27.1%.
Is Passage Bio's 3-Year EBITDA Growth Rate too high?
Passage Bio's current 3-Year EBITDA Growth Rate of 34.90% is 144% above median its 10-year median of 14.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Passage Bio's value of 34.90% is 133.4% above this industry median. Based on the distribution chart, Passage Bio ranks #308 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Passage Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 3-Year EBITDA Growth Rate compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #308 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Passage Bio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.95. Passage Bio's value of 34.90% is 133.4% above this benchmark. While the company's 10-year median is 14.30 vs. the industry median of 14.95, Passage Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current 3-Year EBITDA Growth Rate of 34.90% is 133.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Passage Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current 3-Year EBITDA Growth Rate is 34.90%, which is 144% above median its own 10-year median of 14.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 3-Year EBITDA Growth Rate of 34.90%. The current 3-Year EBITDA Growth Rate is 34.90%, which is 144% above median its 10-year median of 14.30 and 133.4% above the Biotechnology industry median of 14.95. Passage Bio's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Passage Bio (PASG), the current 3-Year EBITDA Growth Rate is 34.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
32GF Score
Get the complete analysis for PASG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
